Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sebastian Medina
Institutions:
Georgia Institute of Technology,
Emory University,
The Wallace H. Coulter Department of Biomedical Engineering
Observed institutions:
Georgia Institute of Technology,
Emory University,
The Wallace H. Coulter Department of Biomedical Engineering
ORCID:
0000-0002-4154-0519
Observed ORCID:
0000-0002-4154-0519
OpenAlex ID:
A5125093843
Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B-41 Clinical Trial Validation
2026
·
Satvika Bharadwaj
, Germán Corredor
, et al.
·
Clinical Cancer Research
·
1
834 Computational Pathology Captures Nuclear Morphology Alterations Following Neoadjuvant Chemohormonal Therapy (NCHT) in High Risk Localized Prostate Cancer
2026
·
Sebastian Medina
, Puchangxin Li
, et al.
·
Laboratory Investigation
Supplementary Figure S3 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S14 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S9 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Table S5 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S10 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S12 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S8 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S5 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S11 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Table S3 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S6 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S4 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Table S2 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Table S1 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S13 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Methods S1 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S1 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Table S4 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S7 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Supplementary Figure S2 from A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer
2026
·
Sebastian Medina
, Naoto Tokuyama
, et al.
Show more works
View as search
Works count:
22
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type